SparingVision SparingVision
Our Mission

Translating Pioneering Science into Vision-Saving Treatments

cropped-SPVN_Favicon.png
Our Company

Moving beyond single gene correction therapies to deliver new treatments.

We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by blinding retinal diseases, regardless of genetic cause.

SPVN_ICON_DNA
Genomic Medicines

Our goal is to harness the potential of gene therapy to bring cutting-edge innovation into ocular disease drug discovery and development.

SPVN_ICON_MIC
Pipeline
At the heart of this is a pipeline of mutation independent treatments for Inherited Retinal Diseases (IRD) such as Retinitis Pigmentosa (RP), as well as dry AMD and Geographic Atrophy (GA).
SPVN_ICON_EYE_X
Retinitis Pigmentosa
A group of IRDs which are a leading cause of blindness globally. Current treatment approaches are not applicable to all patients, regardless of genetic background or disease stage. With our comprehensive approach for RP, we believe that we can bring meaningful differences to most of them.
SPVN_ICON_Gene
0
+
Mutations in more than 70 genes
are known to cause RP
SPVN_ICON_France
0
Forty thousand people
are affected by RP in France
SPVN_ICON_Globe
0
M
Two million people are
affected by RP in the world
SPVN_ICON_Globe

SPVN06

SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).

Learn More
cropped-SPVN_Favicon.png

Combining 20+ years of world-leading ophthalmic research with a world class team of experts from across the international drug development spectrum. SparingVision has an unparalleled understanding of retinal disease and bringing novel treatments to patients.

Investors
Public Funding
01

Patients
02

Technology
03

Pipeline

© SparingVision